BostonGene vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
BostonGene is an AI-powered precision oncology company using multiomics and tumor microenvironment analysis to guide cancer treatment; won Frost & Sullivan's 2025 Global Tech Innovation Award and partnered with Johnson & Johnson.
About
BostonGene is a biomedical company founded in 2015 that applies artificial intelligence and next-generation sequencing to decode cancer patients' molecular profiles, enabling oncologists and biopharma researchers to make more precise treatment decisions. Its AI-powered multiomics platform analyzes tumor microenvironments, genomic drivers, and immune system interactions to identify the most effective therapy for each patient, reducing trial-and-error in cancer treatment selection.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.